Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mum On Takeda, Shire Outlines Two-Division Performance

Executive Summary

Before the March 28 announcement of Takeda’s interest in buying Shire, the focus of Shire’s first quarter earnings call was expected to be the initial reporting of financial results for rare disease and neuroscience as separate units. Sales for the former grew, but declined for the latter.

You may also be interested in...



Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk

Stakeholders are eager for details on the Takeda/Shire merger and on what Trump said to Pfizer CEO Ian Read to cause the recent about-face on price increases. Other key topics will be status updates on Teva's Copaxone franchise and on Novo Nordisk's oral semaglutide.

Allergan Fights Generic Headwinds, Activist Investors

Chairman/CEO Saunders says the board has determined that keeping him in the dual role is the right move going forward. He added that the company, which had a strong second quarter, won’t be rushed in its efforts to divest its women’s health and infectious disease units.

Takeda Closes In On Shire With Revised £49/Share Offer

Takeda further ups its offer for Shire to around £49 per share, which Shire’s board has said it is willing to recommend to shareholders, although any final deal remains subject to conditions and Takeda investors appear concerned over the size of the transaction.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

CO180755

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel